Last updated: February 4, 2026
Summary
Eisai Co., Ltd. filed a patent infringement suit against Glenmark Pharmaceuticals Limited in the U.S. District Court for the District of Delaware. The case concerns Glenmark’s alleged infringement of patents related to Eisai’s epilepsy drug, Levetiracetam. The proceedings began in 2019 and involve complex patent disputes over formulations and manufacturing methods of the branded pharmaceutical.
Key Case Details
- Case Number: 1:19-cv-01214
- Filing Date: June 18, 2019
- Jurisdiction: U.S. District Court for the District of Delaware
- Parties:
- Plaintiff: Eisai Co., Ltd.
- Defendant: Glenmark Pharmaceuticals Limited
Patent Claims and Disputed Technology
Eisai accuses Glenmark of infringing on patents primarily related to U.S. Patent Nos. 9,081,231 and 9,347,216. These patents cover methods for manufacturing levetiracetam with specific purity and formulation characteristics. The patents aim to protect Eisai’s proprietary drug formulation marketed as Keppra.
Glenmark argues that its generic version does not infringe on these patents and challenges their validity on grounds of obviousness and prior art references. Glenmark’s generic is purportedly manufactured using different methods that avoid patent claims.
Legal Proceedings & Developments
- Initial Complaint (2019): Eisai alleged patent infringement and sought injunctive relief and damages.
- Glenmark’s Response: Filed a motion to dismiss, contesting patent validity and non-infringement.
- Patent Disputes: The case involves interrogatories, expert testimony, and claim construction hearings.
- Potential Outcomes:
- Infringement ruling: Court finds Glenmark’s product infringes or not.
- Validity challenge: Court evaluates whether the patents are valid under statutory criteria.
- Settlement or licensing: Parties may settle before trial.
Patent Validity and Infringement Challenges
Glenmark’s defenses focus on:
- Invalidity due to obviousness under 35 U.S.C. § 103.
- Non-infringement based on different manufacturing processes.
- Prior art references that allegedly anticipate or render obvious the patented claims.
Eisai counters these arguments by emphasizing the novelty and non-obviousness of its manufacturing process, supported by expert testimony.
Market and R&D Implications
This patent dispute bears significance for the generics market of levetiracetam. If Glenmark succeeds in invalidating Eisai’s patents or proving non-infringement, it could accelerate the entry of generic versions, impacting Eisai’s market share and revenue.
Case Status and Future Implications
As of the latest update in 2023, the case remains active, with ongoing motions regarding claim construction and summary judgment. A trial date has not been scheduled.
The outcome of this litigation will influence patent enforcement strategies in the neurological therapeutics segment and set precedents for manufacturing method claims.
Key Takeaways
- The case centers on patent rights related to levetiracetam formulations.
- Glenmark challenges both infringement and patent validity.
- The dispute influences generics entry and market competition.
- The legal process involves claim construction, validity arguments, and infringement analyses.
- No final resolution has been reached; litigation continues.
FAQs
1. What patents are involved in the lawsuit?
U.S. Patent Nos. 9,081,231 and 9,347,216, related to manufacturing and formulation methods for levetiracetam.
2. What are the main defenses Glenmark raises?
They argue patent invalidity due to obviousness and non-infringement based on different manufacturing processes.
3. How could this case impact the pharmaceutical market?
A ruling in favor of Glenmark could allow earlier entry of generic levetiracetam, reducing Eisai’s market exclusivity.
4. Has a trial date been scheduled?
No, as of 2023, the case remains pending with ongoing pre-trial motions.
5. Why are patent disputes like this significant?
They determine the scope of patent protections, influence drug pricing, and affect market competition for branded and generic drugs.
References
- Court docket: United States District Court for the District of Delaware, Case No. 1:19-cv-01214.
